ORIGINAL RESEARCH article
Front. Immunol.
Sec. Molecular Innate Immunity
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1654078
This article is part of the Research TopicHereditary Angioedema - C1INH Deficiency and BeyondView all articles
Evaluating Functional C1INH with Multiple Laboratory Methods across Hereditary Angioedema Types Functional C1INH in HAE: Multiple Techniques
Provisionally accepted- 1Faculdade de Medicina do ABC, Santo André, Brazil
- 2Universidade Federal do Rio de Janeiro Hospital Universitario Clementino Fraga Filho, Rio de Janeiro, Brazil
- 3Universidade de Sao Paulo, São Paulo, Brazil
- 4Universidade Estadual de Campinas Faculdade de Ciencias Medicas, Campinas, Brazil
- 5Universidade Federal de Sao Paulo, São Paulo, Brazil
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent episodes of edema and classified into HAE with C1 inhibitor deficiency (HAE-C1INH types 1 and 2) and HAE with normal C1INH (HAE-nC1INH). This study evaluates the function of C1 inhibitor functional of C1 inhibitor (fC1INH) in patients with suspected HAE using several laboratory methods: DBS (dried blood spot), chromogenic assay and ELISA with FXIIa and PKa (plasma kallikrein). The comparative approach aims to improve early detection and understanding of C1INH dysfunction in all HAE subtypes to reflect real-world diagnostic scenarios.We assessed the diagnostic performance of four fC1INH assays in a cohort of 148 HAE patients: 84 with HAE-C1INH (72 Type 1 and 12 Type 2) and 64 with HAE-nC1INH (53 HAE-FXII and 11 HAE-UNK). The gold-standard chromogenic assay and the two substratespecific ELISAs (PKa and FXIIa) were compared to a novel DBS-based LC-MS/MS assay using endogenous C1s activity. For all fC1INH assays, values >50% were considered within the normal range.In HAE-C1INH, the DBS assay showed the highest specificity (Type 1: 98.6%, Type 2: 100%) and 100% sensitivity for both subtypes. ELISA-FXIIa also performed well (specificity: 97.2% and 91.7%). In contrast, ELISA-PKa and the chromogenic assay showed reduced specificity in Type 2 (25% and 66.7%, respectively). Among patients with HAE-FXII, fC1INH levels were reduced by 36.5% by ELISA-FXIIa (19/52), 19.1% by DBS (9/47), and 3.8% by ELISA-PKa (2/52), no alterations were detected by the chromogenic assay. Some of the changes seen in other tests may be partly related to pregnancy in few patients. In the HAE-UNK group, all 11 patients had fC1INH >50% in all methods.DBS-based LC-MS/MS and ELISA-FXIIa offer promising accuracy and broader applicability for early diagnosis of HAE types 1 and 2. The use of novel substrates and inclusion of a clinically realistic cohort may enhance the translational relevance of these findings.
Keywords: hereditary angioedema, C1 Inhibitor, Factor XII, Complement C4, biomarker, diagnosis
Received: 25 Jun 2025; Accepted: 04 Aug 2025.
Copyright: © 2025 Bardou, Constanitno-Silva, Alonso, Teixeira, Giavina-Bianchi, Mansour, Pesquero, Valle and Grumach. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Maine Luellah Demaret Bardou, Faculdade de Medicina do ABC, Santo André, Brazil
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.